LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 175

Search options

  1. Article ; Online: The Future of Vasculitis: A Manifesto.

    Monach, Paul A

    Rheumatic diseases clinics of North America

    2023  Volume 49, Issue 3, Page(s) 713–729

    Abstract: Predictions for a general path forward in vasculitis care and research are provided based on advances made in the past 20 years. Prospects for advances in translational research with potential to improve care are highlighted, including identification of ... ...

    Abstract Predictions for a general path forward in vasculitis care and research are provided based on advances made in the past 20 years. Prospects for advances in translational research with potential to improve care are highlighted, including identification of hemato-inflammatory diseases, autoantigens, disease mechanisms in animal models, and biomarkers. A list of active randomized trials is provided, and areas of potential paradigm shifts in care are highlighted. The importance of patient involvement and international collaboration is noted, and a plea is made for innovative trial designs that would improve access of patients to trials and to clinical experts at referral centers.
    MeSH term(s) Animals ; Humans ; Takayasu Arteritis ; Biomarkers ; Forecasting ; Giant Cell Arteritis
    Chemical Substances Biomarkers
    Language English
    Publishing date 2023-04-15
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 92118-x
    ISSN 1558-3163 ; 0889-857X
    ISSN (online) 1558-3163
    ISSN 0889-857X
    DOI 10.1016/j.rdc.2023.03.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Complement.

    Monach, Paul A

    Arthritis & rheumatology (Hoboken, N.J.)

    2023  Volume 76, Issue 1, Page(s) 1–8

    Abstract: The role of complement in human autoimmune, inflammatory, and infectious diseases is reviewed, focusing on clinical applicability. A typical case is presented in which serum testing for C3 and C4 is performed to help assess a syndrome with a broad ... ...

    Abstract The role of complement in human autoimmune, inflammatory, and infectious diseases is reviewed, focusing on clinical applicability. A typical case is presented in which serum testing for C3 and C4 is performed to help assess a syndrome with a broad differential diagnosis. The review includes a discussion of complement deficiency states, consumption of complement by diseases characterized by immune-complex formation and deposition, usefulness and interpretation of laboratory tests for complement, and development of drugs targeting specific components of the complement pathway for a growing number of indications.
    MeSH term(s) Humans ; Complement C4 ; Complement C3 ; Complement System Proteins ; Syndrome
    Chemical Substances Complement C4 ; Complement C3 ; Complement System Proteins (9007-36-7)
    Language English
    Publishing date 2023-10-16
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2756371-6
    ISSN 2326-5205 ; 2326-5191
    ISSN (online) 2326-5205
    ISSN 2326-5191
    DOI 10.1002/art.42671
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Moving towards a precision approach for prevention of severe COVID-19.

    Branch-Elliman, Westyn / Monach, Paul A

    Lancet (London, England)

    2023  Volume 401, Issue 10386, Page(s) 1423–1424

    MeSH term(s) Humans ; COVID-19/prevention & control ; Precision Medicine
    Language English
    Publishing date 2023-01-09
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(23)00443-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: More data needed on efficacy and safety of monovalent vaccines against SARS-CoV-2 omicron variants.

    Monach, Paul A / Branch-Elliman, Westyn

    The Lancet. Infectious diseases

    2023  Volume 23, Issue 6, Page(s) 654–655

    MeSH term(s) Humans ; SARS-CoV-2 ; COVID-19 Vaccines ; COVID-19/prevention & control ; Antibodies, Neutralizing ; Antibodies, Viral
    Chemical Substances COVID-19 Vaccines ; Antibodies, Neutralizing ; Antibodies, Viral
    Language English
    Publishing date 2023-04-26
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(23)00274-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Underuse of Antiviral Drugs to Prevent Progression to Severe COVID-19 - Veterans Health Administration, March-September 2022.

    Monach, Paul A / Anand, Sonia T / Fillmore, Nathanael R / La, Jennifer / Branch-Elliman, Westyn

    MMWR. Morbidity and mortality weekly report

    2024  Volume 73, Issue 3, Page(s) 57–61

    Abstract: Antiviral drugs reduce the rate of progression to severe COVID-19 when given to patients with mild-to-moderate disease within 5 days of symptom onset. Despite being recommended for patients at high risk for progression to severe COVID-19 because of age ... ...

    Abstract Antiviral drugs reduce the rate of progression to severe COVID-19 when given to patients with mild-to-moderate disease within 5 days of symptom onset. Despite being recommended for patients at high risk for progression to severe COVID-19 because of age or chronic conditions, reported antiviral use among the general adult population has been ≤35%. To ascertain reasons for underuse of antiviral medications to prevent severe COVID-19 and propose interventions accordingly, a detailed review was conducted of 110 Veterans Health Administration patients with mild-to-moderate infection at high risk for progression because of underlying conditions (organ transplantation or hematologic malignancies) who did not receive an antiviral drug. Among these 110 patients, all of whom had received COVID-19 vaccine, 22 (20.0%) were offered treatment but declined, and 88 (80.0%) were not offered treatment. Among the 88 patients not offered treatment, provider reasons included symptom duration of >5 days (22.7%), concern about possible drug interactions (5.7%), or absence of symptoms (22.7%); however, among nearly one half (43 of 88; 48.9%) of these patients, no reason other than mild symptoms was given. Among 24 (55.8%) of those 43 patients, follow-up was limited to telephone calls to report test results and inquire about symptom evolution, with no documentation of treatment being offered. These findings suggest that education of patients, providers, and medical personnel tasked with follow-up calls, combined with advance planning in the event of a positive test result, might improve the rate of recommended antiviral medication use to prevent severe COVID-19-associated illness, including death.
    MeSH term(s) Adult ; Humans ; COVID-19 ; SARS-CoV-2 ; COVID-19 Vaccines ; Veterans Health ; Antiviral Agents/therapeutic use
    Chemical Substances COVID-19 Vaccines ; Antiviral Agents
    Language English
    Publishing date 2024-01-25
    Publishing country United States
    Document type Journal Article
    ZDB-ID 412775-4
    ISSN 1545-861X ; 0149-2195
    ISSN (online) 1545-861X
    ISSN 0149-2195
    DOI 10.15585/mmwr.mm7303a2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Assessing Performance of Internal Medicine Residents.

    Monach, Paul A

    JAMA

    2017  Volume 317, Issue 12, Page(s) 1276–1277

    MeSH term(s) Attitude of Health Personnel ; Clinical Competence ; Humans ; Internal Medicine/education ; Internship and Residency
    Language English
    Publishing date 2017--28
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2017.0890
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Utility of lower extremity magnetic resonance imaging followed by muscle biopsy for myeloperoxidase-antineutrophil cytoplasmic antibodies positive antineutrophil cytoplasmic antibody-associated vasculitis: a single-centre study.

    Jinno, Sadao / Monach, Paul A / Nakazawa, Takashi

    Clinical and experimental rheumatology

    2022  Volume 41, Issue 4, Page(s) 984

    MeSH term(s) Humans ; Antibodies, Antineutrophil Cytoplasmic ; Peroxidase ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnostic imaging ; Biopsy ; Muscles/chemistry
    Chemical Substances Antibodies, Antineutrophil Cytoplasmic ; Peroxidase (EC 1.11.1.7)
    Language English
    Publishing date 2022-05-19
    Publishing country Italy
    Document type Letter
    ZDB-ID 605886-3
    ISSN 1593-098X ; 0392-856X
    ISSN (online) 1593-098X
    ISSN 0392-856X
    DOI 10.55563/clinexprheumatol/eqd0ch
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Improving COVID-19 Disease Severity Surveillance Measures: Statewide Implementation Experience.

    Doron, Shira / Monach, Paul A / Brown, Catherine M / Branch-Elliman, Westyn

    Annals of internal medicine

    2023  Volume 176, Issue 6, Page(s) 849–852

    Abstract: Measurement of the burden of COVID-19 on U.S. hospitals has been an important element of the public health response to the pandemic. However, because of variation in testing density and policies, the metric is not standardized across facilities. Two ... ...

    Abstract Measurement of the burden of COVID-19 on U.S. hospitals has been an important element of the public health response to the pandemic. However, because of variation in testing density and policies, the metric is not standardized across facilities. Two types of burdens exist, one related to the infection control measures that patients who test positive for SARS-CoV-2 require and one from the care of severely ill patients receiving treatment of COVID-19. With rising population immunity from vaccination and infection, as well as the availability of therapeutics, severity of illness has declined. Prior research showed that dexamethasone administration was highly correlated with other disease severity metrics and sensitive to the changing epidemiology associated with the emergence of immune-evasive variants.
    On 10 January 2022, the Massachusetts Department of Public Health began requiring hospitals to expand surveillance to include reports of both the total number of "COVID-19 hospitalizations" daily and the number of inpatients who received dexamethasone at any point during their hospital stay. All 68 acute care hospitals in Massachusetts submitted COVID-19 hospitalization and dexamethasone data daily to the Massachusetts Department of Public Health over a 1-year period. A total of 44 196 COVID-19 hospitalizations were recorded during 10 January 2022 to 9 January 2023, of which 34% were associated with dexamethasone administration. The proportion of patients hospitalized with COVID-19 who had received dexamethasone was 49.6% during the first month of surveillance and decreased to a monthly average of approximately 33% by April 2022, where it has remained since (range, 28.7% to 33%).
    Adding a single data element to mandated reporting to estimate the frequency of severe COVID-19 in hospitalized patients was feasible and provided actionable information for health authorities and policy makers. Updates to surveillance methods are necessary to match data collection with public health response needs.
    MeSH term(s) Humans ; COVID-19/epidemiology ; SARS-CoV-2 ; Patient Acuity ; Hospitals ; Dexamethasone/therapeutic use
    Chemical Substances Dexamethasone (7S5I7G3JQL)
    Language English
    Publishing date 2023-05-16
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 336-0
    ISSN 1539-3704 ; 0003-4819
    ISSN (online) 1539-3704
    ISSN 0003-4819
    DOI 10.7326/M23-0618
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Editorial: Defining and Refining the Risk of Venous Thromboembolism in Giant Cell Arteritis.

    Monach, Paul A

    Arthritis & rheumatology (Hoboken, N.J.)

    2016  Volume 69, Issue 1, Page(s) 3–5

    MeSH term(s) Giant Cell Arteritis ; Humans ; Risk Factors ; Venous Thromboembolism
    Language English
    Publishing date 2016-12-22
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2756371-6
    ISSN 2326-5205 ; 2326-5191
    ISSN (online) 2326-5205
    ISSN 2326-5191
    DOI 10.1002/art.39846
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Not What Anyone Signed up for: Unnecessary and Insurmountable Barriers Encountered in Conducting Clinical Trials in COVID-19.

    Branch-Elliman, Westyn / Monach, Paul A

    Narrative inquiry in bioethics

    2021  Volume 11, Issue 1, Page(s) 8–15

    MeSH term(s) Biomedical Research/ethics ; COVID-19 ; Humans ; Informed Consent ; Pandemics ; Research Design ; SARS-CoV-2
    Language English
    Publishing date 2021-07-27
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2632728-4
    ISSN 2157-1740 ; 2157-1732
    ISSN (online) 2157-1740
    ISSN 2157-1732
    DOI 10.1353/nib.2021.0003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top